Form 4: Sera Prognostics Director Mansoor Raza Mirza Acquires Shares and Options

Director Mansoor Raza Mirza reports acquisition of shares and options in Sera Prognostics, Inc. through restricted stock units and stock options.

Summary

• On June 6, 2024, Mansoor Raza Mirza, a director of Sera Prognostics, Inc., acquired 7,117 shares of Class A Common Stock through restricted stock units (RSUs).
• These RSUs vest in monthly installments over one year, starting June 6, 2024.
• Mirza also acquired 10,549 stock options with an exercise price of $8.43.
• These options also vest in monthly installments over one year, starting June 6, 2024, and expire on June 6, 2034.
• The grants were made pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan.
• Following these transactions, Mirza directly owns 7,117 shares of Class A Common Stock and 10,549 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director is generally a positive sign, indicating confidence in the company. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.
• The vesting schedule aligns the director's interests with the long-term performance of the company.
• The grants are part of a pre-existing compensation policy, indicating a structured approach to director compensation.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the director.

Industry Context

Director ownership and equity-based compensation are common practices in publicly traded companies to align management's interests with those of shareholders. This filing reflects standard compensation practices.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice across the biotech industry.
• Companies like Myriad Genetics and Natera also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.
• The equity grants incentivize the director to contribute to the company's success, benefiting all stakeholders.

Key Dates